Singapore, April 29, 2013 — Veolia Water Solutions & Technologies (Veolia) has been chosen to expand existing water treatment facilities for the second phase of a new bioscience facility in Singapore.
Under this project, Veolia will add AnoxKaldnes™ MBBR (moving bed bioreactor) to existing wastewater treatment facilities, and ORION® technology to process water treatment systems.
- AnoxKaldnes™ MBBRis an efficient and compact wastewater treatment technology that operates as a fixed-film process without activated sludge. In this innovation, specially engineered plastic carriers, coated with microorganism-filled biofilm, are suspended in a reactor to provide a large surface area for trapping sewage.
- Specially designed for pharmaceutical and healthcare businesses, ORION® packaged systems are pre-validated and skid-mounted. The technology features 80 standard configurations, of which ORION® 17,000 was selected to meet the new plant’s requirements.
AnoxKaldnes™ MBBR will treat 700m3 of wastewater a day, while ORION® has an hourly capacity of 17m3 of process water.
The combination of this project and the previous contract secured for the first phase of the Bioscience facility enforces Veolia’s longstanding relationship with the global healthcare company globally.
Céline DRONSART, Pharmaceutical & Cosmetics Market Manager, Design & Build Projects, South East Asia Industrial, said, “This project reinforces Veolia’s reputation within the industry, and we anticipate that this will heighten awareness about our expertise for this sector. We look forward to expanding our offerings in the pharmaceutical industry as Veolia secures more projects in the coming years.”
Publish your content with EB Publishing
It's about who you reach. Get your news, events, jobs and thought leadership seen by those who matter to you.
